|
1.
|
|
|
2.
|
|
8 p, 500.4 KB |
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
/
Siena, S. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Sartore-Bianchi, A. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
García-Carbonero, Rocío (Universidad Complutense de Madrid) ;
Karthaus, M. (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ;
Smith, D. (Bordeaux University Hospital (França)) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Van Cutsem, E. (KU Leuven, Leuven, Belgium) ;
Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ;
Boedigheimer, M. (Amgen Inc., Thousand Oaks, CA, USA) ;
Ang, A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Twomey, B. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bach, B. A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Jung, A. S. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bardelli, Alberto (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 -  10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126
|
|
|
3.
|
|
7 p, 242.6 KB |
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies
/
Boeckx, N. (University Hospital Antwerp (Bèlgica)) ;
Koukakis, R. (Biostatistics, Amgen Ltd) ;
Op de Beeck, K. (University Hospital Antwerp (Bèlgica)) ;
Rolfo, Christian (University Hospital Antwerp (Bèlgica)) ;
Van Camp, G. (University Hospital Antwerp (Bèlgica)) ;
Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Douillard, Jean-Yves (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ;
André, Thierry (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica))
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868
|
|
|
4.
|
|
7 p, 814.0 KB |
Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma : results from a randomised controlled trial
/
Siena, Salvatore (Università degli Studi di Milano (Italy)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Bodoky, Gyorgy (St László Hospital (Hongria)) ;
Cunningham, David (Royal Marsden National Health Service Foundation Trust (United Kingdom)) ;
Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Ruff, Paul (University of the Witwatersrand (South Africa)) ;
Canon, Jean Luc (Grand Hôpital de Charleroi. Service d'Oncologie-Hématologie (Belgium)) ;
Koukakis, Reija (Amgen Ltd. Department of Biostatistics (United Kingdom)) ;
Demonty, Gaston (Amgen GmbH. Medical Development (Suïssa)) ;
Hechmati, Guy (Amgen GmbH. Global Health Economics (Suïssa)) ;
Douillard, Jean-Yves (Institut de Cancérologie de l'Ouest (France)) ;
Universitat Autònoma de Barcelona
Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. [...]
2016 - 10.1136/esmoopen-2016-000041
ESMO open, Vol. 1, Issue 2 (March 2016) , art. e000041
|
|
|
5.
|
|
6 p, 180.0 KB |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
/
Ramanathan, R. K. (Mayo Clinic (USA)) ;
Goldstein, D. (Prince of Wales Hospital (Australia)) ;
Korn, R. L. (Scottsdale Medical Imaging, Ltd (USA)) ;
Arena, F. P (NYU Langone Arena Oncology (USA)) ;
Moore, M. (Provencial Health Services Authority. BC Cancer Agency (Canada)) ;
Siena, S. (Università degli Studi di Millano. Niguarda Cancer Center (Italy)) ;
Teixeira, L. (Hôpital Saint-Antoine (Paris, França)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Van Laethem, J.-L. (University Clinic of Brussels. Hôpital Erasme (Belgium)) ;
Liu, H. (Biostatistics and Research and Design. Celgene Corporation (USA)) ;
McGovern, D. (Biostatistics and Research and Design. Celgene Corporation (USA)) ;
Lu, B. (Biostatistics and Research and Design. Celgene Corporation (USA)) ;
Von Hoff, D. D. (Translational Genomics Research Institute) ;
Universitat Autònoma de Barcelona
In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. [...]
2016 - 10.1093/annonc/mdw020
Annals of oncology, Vol. 27, Issue 4 (April 2016) , p. 648-653
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
